Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 11/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171819 | 0.84 | KIF11 (0.51) | TRPV4KIF11ARALDH1A1CYP2A6 | |
| SCHEMBL19726590 | 0.82 | KIF11 (0.44) | TRPV4KIF11ARALDH1A1CYP2A6 | |
| SCHEMBL7569957 | 0.81 | TRPV4 (0.58) | TRPV4KIF11AR | |
| SCHEMBL16957015 | 0.80 | NOTUM (0.36) | TRPV4KIF11CTSSCTSKAR | |
| SCHEMBL6211552 | 0.80 | NOTUM (0.40) | TRPV4KIF11CTSSCTSKAR | |
| SCHEMBL7604551 | 0.79 | TRPV4 (0.56) | TRPV4KIF11AR | |
| SCHEMBL8225797 | 0.78 | TRPV4 (0.56) | TRPV4KIF11ARALDH1A1 | |
| SCHEMBL16019370 | 0.78 | TRPV4 (0.56) | TRPV4KIF11ARALDH1A1 | |
| SCHEMBL10502974 | 0.78 | TRPV4 (0.54) | TRPV4KIF11AR | |
| SCHEMBL1003776 | 0.78 | AR (0.58) | TRPV4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111072636-B | Synthesis method of flumatinib | 江苏豪森药业集团有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-111072636-A | Synthesis method of flumatinib | 江苏豪森药业集团有限公司 | 2020-04-28 | — | — | CN | claimed |
| CN-104710367-A | Method for synthesizing enzalutamide | UNIV CHINA PHARMA | 2015-06-17 | — | — | CN | claimed |
| CN-101460467-B | Diarylthiohydantoin compounds | UNIV CALIFORNIA | 2012-09-19 | — | — | CN | claimed |
| CN-101460467-A | Diarylthiohydantoin compounds | UNIV CALIFORNIA (US) | 2009-06-17 | — | — | CN | claimed |
| US-20260034126-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240218004-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240224783-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240209013-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-06-27 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-5589497-A | ANTIANDROGENS | Uclaf, Roussel (FR) | 1996-12-31 | — | — | US | disclosed |
| US-5556983-A | ANTIANDROGENS | ROUSSEL UCLAF (FR) | 1996-09-17 | — | — | US | disclosed |
| US-5434176-A | Antiandrogens | ROUSSEL UCLAF (FR) | 1995-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034126-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | TRPV4 4786/4885KIF11 2789/4885CTSS 2919/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | TRPV4 2452/4885KIF11 4039/4885CTSS 951/4885 |
| US-20240224783-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | TRPV4 78/4885KIF11 3780/4885CTSS 390/4885 |
| US-20240209013-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, SSB, L1CAM | TRPV4 1438/4885KIF11 3381/4885CTSS 2274/4885 |
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | TRPV4 1849/4885KIF11 4591/4885CTSS 3765/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | TRPV4 3329/4885KIF11 4555/4885CTSS 1940/4885 |
| US-20240218004-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, CCND2 | TRPV4 504/4885KIF11 1809/4885CTSS 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.